BridgeBio Pharma shares fell after analysts cited risks from Pfizer’s Vyndamax losing exclusivity, pressuring its rival drug Attruby.
BridgeBio Pharma (BBIO) shares declined in premarket trading Tuesday after Raymond James downgraded the stock. The downgrade reflects concerns over Pfizer’s (PFE) Vyndamax, a competing heart drug, losing market exclusivity, which could increase competition for BridgeBio’s lead asset, Attruby.
The downgrade follows Vyndamax’s recent loss of exclusivity, a development that may expand generic or biosimilar competition. Attruby, BridgeBio’s primary drug candidate, targets similar indications, leaving it vulnerable to pricing and market share pressures.
No immediate market reaction details were provided beyond the premarket share decline.